New Horizon Health (HKSE:06606) Debt-to-EBITDA : 12.69 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is New Horizon Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

New Horizon Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$26 Mil. New Horizon Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$464 Mil. New Horizon Health's annualized EBITDA for the quarter that ended in Jun. 2023 was HK$39 Mil. New Horizon Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 12.69.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for New Horizon Health's Debt-to-EBITDA or its related term are showing as below:

HKSE:06606' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.33 Med: -0.2 Max: 65.15
Current: 65.15

During the past 5 years, the highest Debt-to-EBITDA Ratio of New Horizon Health was 65.15. The lowest was -5.33. And the median was -0.20.

HKSE:06606's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.26 vs HKSE:06606: 65.15

New Horizon Health Debt-to-EBITDA Historical Data

The historical data trend for New Horizon Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Horizon Health Debt-to-EBITDA Chart

New Horizon Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

-0.06

-0.91

-0.20

-0.04

-5.33

New Horizon Health Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-EBITDA	Get a 7-Day Free Trial				-0.02	-0.32	-1.08	-11.61	12.69

Competitive Comparison of New Horizon Health's Debt-to-EBITDA

For the Medical Devices subindustry, New Horizon Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

New Horizon Health's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where New Horizon Health's Debt-to-EBITDA falls into.

New Horizon Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

New Horizon Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(22.163	+	251.419)	/	-51.336
	=	-5.33

New Horizon Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(26.101	+	463.915)	/	38.614
	=	12.69

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.

New Horizon Health (HKSE:06606) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

New Horizon Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of New Horizon Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

New Horizon Health (HKSE:06606) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » New Horizon Health Ltd (HKSE:06606) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

6YZ:Germany

Address

400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052

Website

https://ir.newhorizonbio.com

New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.

Executives

Invesco Advisers, Inc.	2102 Investment manager
Chen Yiyou	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Bancasa Holding Limited	2201 Interest of corporation controlled by you
Mst Development Limited	2101 Beneficial owner
Yao Naxin	2305 Beneficiary of a trust
Janus Henderson Group Plc	2102 Investment manager
Jpmorgan Chase & Co.	2106 Person having a security interest in shares
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Zhu Yeqing	2101 Beneficial owner
Qiming Venture Partners V, L.p.
Qiming Gp V, L.p.
Qiming Corporate Gp V, Ltd.
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

New Horizon Health (HKSE:06606) Headlines

No Headlines